TriangleSBRT + atezolizumab and bevacizumab (NCT05488522)
SBRT + atezolizumab and bevacizumab trial for Unresectable Hepatocellular Carcinoma (NCT05488522). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
Lo que dice el vídeo
Lee la transcripción
This trial is for advanced hepatocellular carcinoma, a liver cancer, that cannot be treated with curative surgery or ablation and needs systemic therapy, in adults.
The idea: repeat radiation alongside immunotherapy. Stereotactic body radiotherapy is given in repeated doses together with atezolizumab and bevacizumab. Both drugs are FDA approved for advanced liver cancer in combination.
This phase 1 study raises the radiation dose in steps to find a safe dose, and plans 18 patients. At the Abramson Cancer Center at Penn Medicine in Philadelphia, Edgar Ben-Josef leads it.
Public record; not medical advice.
¿Ya estás en un ensayo?
Se convierte en un proyecto que hay que manejar: citas, estudios de imagen, análisis, efectos secundarios y papeleo. Triangle lo mantiene organizado en un solo lugar, para ti o para quien te ayuda.
Organizar mi ensayoPrueba gratuita de 7 días, después $9 al mes. Cancela cuando quieras.
Cómo funcionan estos ensayos: qué es de verdad la fase 1 · preguntas frecuentes No es evidencia clínica.